Nordicus Partners Corp. Files S-1/A Amendment

TL;DR

Nordicus Partners Corp (NORD) filed an S-1/A, updating its filing status. Check for new details.

AI Summary

Nordicus Partners Corp. filed an S-1/A amendment on December 23, 2024, detailing its business operations and financial status. The company, formerly known as EKIMAS Corp, AdvanSource Biomaterials Corp, and CARDIOTECH INTERNATIONAL INC, is incorporated in Delaware and operates in management consulting services. Its fiscal year ends on March 31.

Why It Matters

This filing provides updated information for investors and the public regarding Nordicus Partners Corp.'s corporate structure, financial reporting, and any potential changes in its business or securities.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate a company is preparing for significant corporate actions like an IPO or offering, which inherently carry market and execution risks.

Key Numbers

• 20241223 — Filing Date (Date the S-1/A amendment was filed)
• 0331 — Fiscal Year End (Indicates the end of the company's financial reporting year)

Key Players & Entities

• Nordicus Partners Corp (company) — Filer of the S-1/A
• EKIMAS Corp (company) — Former name of Nordicus Partners Corp
• AdvanSource Biomaterials Corp (company) — Former name of Nordicus Partners Corp
• CARDIOTECH INTERNATIONAL INC (company) — Former name of Nordicus Partners Corp
• 280 SOUTH BEVERLY DR. SUITE 505 (address) — Business and mailing address
• BEVERLY HILLS, CA 90212 (address) — Business and mailing address
• 508-523-3141 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $2.76 — rted sale price of our common stock was $2.76 Investing in our securities involves
• $400,000 — tanding for total cash consideration of $400,000. Reddington purchased in two tranches o
• $0.001 — f the Company's common stock, par value $0.001 per share. As a result of the Business
• $250 million — Company As a company with less than a $250 million public float and less than $100 million
• $100 million — $250 million public float and less than $100 million in annual revenues and a public float o
• $700 m — evenues and a public float of less than $700 million, we qualify as a "smaller reporti
• $75 million — panies with a public float of less than $75 million; and Reduced disclosure of financial
• $5.00 — ) the stock trades at a price less than $5.00 per share; (ii) it is not traded on a "
• $2.0 m — pany with net tangible assets less than $2.0 million, if in business more than a conti
• $6.0 million — , or with average revenues of less than $6.0 million for the past three years. The principal

Filing Documents

• forms-1a.htm (S-1/A) — 1984KB
• ex5-1.htm (EX-5.1) — 12KB
• ex23-1.htm (EX-23.1) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 16KB
• ex23-1_001.jpg (GRAPHIC) — 18KB
• ex23-1_002.jpg (GRAPHIC) — 13KB
• image_001.jpg (GRAPHIC) — 21KB
• report_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-051214.txt ( ) — 6517KB
• nord-20240930.xsd (EX-101.SCH) — 31KB
• nord-20240930_cal.xml (EX-101.CAL) — 45KB
• nord-20240930_def.xml (EX-101.DEF) — 230KB
• nord-20240930_lab.xml (EX-101.LAB) — 286KB
• nord-20240930_pre.xml (EX-101.PRE) — 269KB
• forms-1a_htm.xml (XML) — 804KB

USE OF PROCEEDS

USE OF PROCEEDS 19 MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 19 SELLING STOCKHOLDERS 20

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 26

BUSINESS

BUSINESS 30 MANAGEMENT 31

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 34 PRINCIPAL SECURITYHOLDERS 37 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 39 MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK 40

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 41 INDEMNIFICATION OF OFFICERS AND DIRECTORS 44 SHARES ELIGIBLE FOR FUTURE SALE 44 PLAN OF DISTRIBUTION 45 LEGAL MATTERS 46 EXPERTS 46 WHERE YOU CAN FIND MORE INFORMATION 46 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 3 PROSPECTUS SUMMARY The following summary highlights information contained elsewhere in this prospectus. This summary may not contain all of the information that may be important to you. You should read this entire prospectus carefully, including the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our historical financial Company," "Nordicus Partners," "NORD," "we," "us," and "our" refer to Nordicus Partners Corporation The Company Overview We are a financial consulting company, specializing in providing Nordic and U.S. life science companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management's combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Organizational History We were founded in 1993 and in 2007 were reincorporated from a Massachusetts corporation to a Delaware corporation. We changed our name from CardioTech International, Inc. to AdvanSource Biomaterials Corporation, effective October 15, 2008. On March 3, 2020, we changed our name to EKIMAS Corporation. On October 12, 2021, we entered into a Stock Purchase Agreement (the "SPA") with Reddington, a California limited liability company, providing for the purchase of a total of 511,448 of our common stock, on a post-split basis discussed below, or approximately 90% of our total shares of common stock outstanding for total cash consideration of $400,000. Reddington purchased in two tranches on Octo

View Full Filing

View this S-1/A filing on SEC EDGAR